Core Viewpoint - YXTT plans to invest 24 million yuan to purchase five properties in Kunming, Yunnan, to develop its medical and elderly care business, which has become a significant part of its operations despite recent declines in net profit [2][3] Company Summary - YXTT's board has approved the purchase of properties for its medical and elderly care business, which is part of its strategic development plan [3] - The medical and elderly care segment has been a focus for YXTT for five years, with the establishment of Yunnan YXTT Medical and Elderly Care Service Co., Ltd. in June 2020 [3] - As of 2024, the medical and elderly care business ranks fourth among YXTT's seven main business segments [3] - YXTT's medical and elderly care services are supported by the Kunming Jinding Geriatric Hospital and the Jinding Mountain Nursing Home, forming a three-tiered integration model [3] Industry Summary - The medical and elderly care market in China reached 1.52 trillion yuan in 2023, with a compound annual growth rate of 20.65% [4] - By the end of 2023, the elderly population aged 60 and above in China approached 300 million, accounting for 21.1% of the total population, indicating a shift towards a moderately aging society [4] - Various stakeholders, including public medical institutions and private entities, are entering the medical and elderly care market, supported by government policies [5] - As of May 2024, there were 87,000 signed agreements between medical and elderly care institutions, with over 7,800 registered medical and elderly care institutions [5] - YXTT's net profit has significantly declined, with figures of 549 million yuan in 2023 and 114 million yuan in 2024, representing year-on-year decreases of 45.60% and 79.23% respectively [6]

Core Viewpoint - YXTT (一心堂) is investing 24 million yuan to purchase five properties in Kunming, Yunnan, to expand its medical and elderly care business, which has become a significant part of its operations despite recent declines in net profit [1][2]. Group 1: Company Strategy - The board of YXTT has approved the acquisition of properties to support its medical and elderly care services, which aligns with the company's long-term development strategy [2]. - YXTT has been developing its medical and elderly care business for five years, establishing a subsidiary in 2020 to enhance its service offerings [2]. - The company has created a three-tiered model for integrated medical and elderly care, leveraging its pharmacy network to provide home care services [2]. Group 2: Market Overview - The medical and elderly care market in China reached a scale of 1.52 trillion yuan in 2023, with a compound annual growth rate of 20.65% [3][4]. - As of the end of 2023, nearly 300 million people aged 60 and above in China represent 21.1% of the total population, indicating a significant demand for medical services [3]. - Various stakeholders, including public medical institutions and private entities, are entering the medical and elderly care market, supported by government policies [4]. Group 3: Financial Performance - YXTT's net profit has declined significantly, with figures of 549 million yuan in 2023 and 114 million yuan in 2024, representing year-on-year decreases of 45.60% and 79.23%, respectively [5]. - The contribution of the medical and elderly care business to YXTT's overall revenue remains small, accounting for only 2.99% of total revenue in 2024 [5].

Group 1 - The overall market size of retail pharmacies in China reached 923.3 billion yuan in 2023, with a CAGR of 7.7% from 2019 to 2023 [1][6] - The number of retail pharmacies has been continuously increasing, totaling 667,000 in 2023, with an average service population per store of approximately 2,114, which is declining [1][6] - The online pharmacy segment has shown significant growth, contributing 78% to the overall sales growth of pharmacies in 2023, with online sales accounting for 33% of total pharmacy sales [9][10] Group 2 - The retail pharmacy market in Yunnan is characterized by high concentration and regional imbalance, with a chain rate of 57.16% [1][23] - Local chain enterprises like Yixin Tang and Jianzhijia are leveraging local resources for deep penetration and are expected to accelerate their expansion outside the province [1][27] - The expansion of Yunnan's leading pharmacy chains outside the province is evident, with Yixin Tang's share of in-province stores decreasing from 59.46% in 2020 to 48.49% in 2024 [27][28] Group 3 - The importance of retail pharmacies has been increasing due to various policies promoting the separation of medicine and healthcare, with the pharmacy channel expected to see accelerated prescription sales [2][29] - The implementation of outpatient coordination is crucial for reducing unnecessary hospital resource occupation and enhancing patient convenience [2][39] - The expected increase in prescription outflow could lead to a market increment of over 1 billion yuan from 2025 to 2027 [2][59] Group 4 - Companies that excel in professional services, diversified operations, and omnichannel strategies are likely to achieve better competitive differentiation and find new growth avenues [3][65] - The online sales channel is becoming increasingly important, with O2O sales expected to rise significantly, potentially reaching 1,444 billion yuan by 2030 [66] - The development of self-owned brands and non-pharmaceutical products can help pharmacies reduce reliance on insurance funds and improve profit margins [62][64]

一心为民 全心服务 近日，公司与华夏银行股份有限公司昆明红塔支行签订了《华夏银行人民币单位结构性存 款业务协议》，现将有关情况公告如下： | 签约银行 | 产品名称 | 认购金额 | 收益类型 | 合同起始日 | 合同到期日 | 产品预期收 | | --- | --- | --- | --- | --- | --- | --- | | 名称 | | （万元） | | | | 益率（年） | | 华夏银行 股份有限 | "节节高"90D | | 保本保最低 | | | 1.00%至 | | | 结构性存款 | 5,000 | | 2025-08-01 | 2025-10-28 | | | 公司昆明 | 2510781 | | 收益型 | | | 2.30% | | 红塔支行 | | | | | | | 股票代码：002727 股票简称：一心堂 公告编号：2025-065 号 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月 ...

Core Viewpoint - The aggressive expansion strategy of the company has led to significant profit erosion, with a 79.23% year-on-year decline in net profit for 2024, marking a historical low since its listing [3][8]. Group 1: Financial Performance - The company reported a net profit of 114 million yuan for 2024, down 79.23% year-on-year, continuing a trend of declining profits for the second consecutive year [3][10]. - The company's revenue for 2024 was 18 billion yuan, reflecting a 3.57% increase compared to the previous year, but the net profit decline indicates a situation of "increased revenue without increased profit" [8][10]. - The company’s revenue sources include 71.88% from pharmaceutical retail, amounting to 12.94 billion yuan, and 22.71% from pharmaceutical wholesale, totaling 4.09 billion yuan [7]. Group 2: Expansion Strategy - The company has adopted a "land grab" strategy, opening over 1,000 new stores annually, with a total of 11,498 stores by the end of 2024, an increase of 1,243 stores from the beginning of the year [8][10]. - The company plans to continue expanding its presence in the Sichuan-Chongqing region while optimizing existing stores rather than significantly increasing the number of new stores [11]. Group 3: Investment in Healthcare Integration - The company has invested 24 million yuan in purchasing properties to enhance its healthcare integration business, which is seen as a strategic move for sustainable development [4][5]. - The healthcare integration business aims to create a network of services including medical care, rehabilitation, nursing, and health management, establishing a comprehensive ecosystem [6]. Group 4: Market Trends and Challenges - The aging population and policy incentives are driving the growth of the elderly care industry, which is projected to reach a market size of 30 trillion yuan by 2035 [5][6]. - Increased competition from online pharmaceutical platforms and tightening regulations have added pressure on traditional retail pharmacies, impacting profit margins [10].

Market Overview - The pharmaceutical commercial sector increased by 1.04% on July 30, with Huaren Health leading the gains [1] - The Shanghai Composite Index closed at 3615.72, up 0.17%, while the Shenzhen Component Index closed at 11203.03, down 0.77% [1] Top Performers - Huaren Health (301408) closed at 15.01, up 5.48% with a trading volume of 334,100 shares and a transaction value of 499 million [1] - Jiazhang Tang (002462) closed at 14.67, up 4.19% with a trading volume of 232,300 shares and a transaction value of 346 million [1] - Laobaixing (603883) closed at 19.69, up 2.93% with a trading volume of 398,800 shares and a transaction value of 779 million [1] - China National Pharmaceutical (600056) closed at 11.28, up 2.64% with a trading volume of 656,900 shares and a transaction value of 747 million [1] Underperformers - Renmin Tongtai (600829) closed at 8.77, down 7.20% with a trading volume of 724,400 shares and a transaction value of 651 million [2] - Saily Medical (603716) closed at 30.89, down 2.31% with a trading volume of 444,300 shares and a transaction value of 1.385 billion [2] - Runda Medical (603108) closed at 18.20, down 1.83% with a trading volume of 299,700 shares and a transaction value of 552 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 62.07 million from institutional investors, while retail investors saw a net inflow of 64.93 million [2] - Major stocks like Laobaixing and China National Pharmaceutical had significant net inflows from retail investors, despite overall sector outflows [3] Individual Stock Analysis - Laobaixing (603883) had a net inflow of 62.57 million from institutional investors, but a net outflow of 45.34 million from retail investors [3] - China National Pharmaceutical (600056) saw a net inflow of 49.86 million from institutional investors, with a net outflow of 43.44 million from retail investors [3] - Huaren Health (301408) had a net inflow of 21.02 million from institutional investors, but a net outflow of 26.49 million from retail investors [3]

Core Viewpoint - The aggressive expansion strategy of the company has led to significant profit erosion, with a drastic decline in net profit for 2024, marking a historical low since its listing [1][5]. Financial Performance - In 2024, the company reported a net profit of 114 million yuan, a year-on-year decrease of 79.23%, continuing a trend of declining profits for the second consecutive year [1][5]. - The company's revenue for 2024 was 18 billion yuan, reflecting a growth of 3.57% compared to the previous year [5]. - The company experienced a decline in net profit and revenue in 2023, with net profit dropping to 549 million yuan, a decrease of 45.6% year-on-year [5]. Expansion Strategy - The company has adopted a "land grab" strategy, opening over 1,000 new stores annually, with a total of 11,498 stores as of December 31, 2024 [4][5]. - The company plans to continue expanding its store presence in the Sichuan-Chongqing region while optimizing existing stores rather than significantly increasing the number of new stores [6]. Business Segments - The company derives 71.88% of its revenue from pharmaceutical retail, amounting to 12.938 billion yuan, while wholesale revenue accounts for 22.71% [3]. - The company is investing 24 million yuan in real estate to enhance its medical and elderly care business, which is seen as a strategic move in response to the growing elderly care market [2][3]. Market Trends - The elderly care market in China is expanding, with a market size of 12 trillion yuan in 2023, expected to reach 30 trillion yuan by 2035 [2]. - The company is integrating medical, rehabilitation, nursing, and elderly care services to create a comprehensive healthcare ecosystem [2][3].

第三条 审计委员会应认真学习中国证监会、证券交易所等监管部门关于年报编制和披 露的工作要求，积极参加其组织的培训。 第四条 审计委员会应与年审会计师事务所协商确定本公司年报审计工作的时间安排。 一心堂药业集团股份有限公司 审计委员会年报工作制度 2025 年 7 月 25 日 一心堂药业集团股份有限公司 审计委员会年报工作制度 第一条 为进一步完善一心堂药业集团股份有限公司（以下简称"公司"）治理机制， 充分发挥董事会审计委员会在年报编制和披露方面的监督作用，维护审计的独立性，根据 中国证监会、深圳证券交易所以及《公司章程》、《董事会审计委员会工作细则》的有关 规定，结合公司实际情况，制定本工作制度。 第二条 公司董事会审计委员会在年报编制和披露过程中，应当按照有关法律、行政法 规、规范性文件和本工作规程的要求，认真履行职责，保证公司年报的真实、准确、完整 和及时。 第五条 审计委员会应督促会计师事务所在约定的时间内提交年报审计报告，以书面意 见形式记录督促的方式、次数和结果，并由相关负责人签字确认。 第六条 审计委员会应在为公司提供年报审计的注册会计师（以下简称"年审会计 师"）进场前审阅公司财务部门编制的 ...

一心堂药业集团股份有限公司 重大信息内部报告制度 2025 年 7 月 25 日 | | 第一章总则 2 | | --- | --- | | 第二章 | 重大信息的范围 2 | | 第三章 | 重大信息内部报告程序 8 | | 第四章 | 重大信息内部报告的管理和责任 9 | | 第五章 | 附则 10 | 一心堂药业集团股份有限公司 重大信息内部报告制度 第一章总则 第一条 为规范一心堂药业集团股份有限公司（以下简称"本公司"或"公司"）重大 信息内部报告工作，保证公司内部重大信息的快速传递、归集和有效管理，及时、准确、全 面、完整地披露信息，维护投资者的合法权益，根据《中华人民共和国公司法》、《中华人民 共和国证券法》、《上市公司信息披露管理办法》、《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等有关法律、法规、规 范性文件和《公司章程》的有关规定，结合公司实际，制定本制度。 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可能对公司股票及其 衍生品种交易价格产生较大影响的情形或事件时，按照本制度规定负有报告义务的有关人员 和公司，应当在第一 ...

一心堂药业集团股份有限公司 年报信息披露重大差错责任追究制度 2025 年 7 月 25 日 1 | 第一章总 | 则 | 3 | | --- | --- | --- | | 第二章 | 财务报告重大会计差错的认定及处理 | 4 | | 第三章 | 其他年报信息披露重大差错的认定及处理程序 | 5 | | 第四章 | 年报信息披露重大差错的责任追究 | 6 | | 第五章 | 附则 | 7 | 一心堂药业集团股份有限公司 年报信息披露重大差错责任追究制度 第一章总 则 第一条 为进一步提高一心堂药业集团股份有限公司（以下简称"公司"） 的规范运作 水平，加大对年报信息披露责任人的问责力度，提高年报信息披露的质量和透明度，增强 信息披露的真实性、准确性、完整性和及时性，推进公司内部制度建设，根据《中华人民 共和国证券法》、《上市公司信息披露管理办法》、《上市公司治理准则》、《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》等法律法规、规范性文件及《公司章程》、《信息披露管理制度》的有关规定，结合公 司实际情况，制定本制度。 第二条 本制度适用于公司年报信息 ...